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Summary 
It is not known whether all forms of cell surface peptide-class I complexes, when bound with 
relevant peptide antigen,  are recognized by T  cells.  We demonstrate  herein  that  two distinct 
subsets of the murine H-2 K b molecule can be separately  isolated from H-2b-expressing cell lines 
using Y3 mAb immunoaffinity chromatography. Although both isolated K b subsets were found 
to be strongly reactive with Y3 mAb by ELISA, one K b subset is S19.8 mAb reactive (Ly-mll + 
K b subset) and exhibits low reactivity with the M1/42 antibody, while the other subset is nega- 
tive for the Ly-mll epitope and highly reactive with the M1/42 antibody (M1/42hig h K b subset). 
More importantly,  whereas the M1/42hig h K b subset is a very effective ligand for both TCR and 
CD8, the Ly-mll + K b subset could only function as a CD8 ligand, as determined in aUo-specific 
CD8 + CTL clone adhesion and degranulation assays. Peptides acid-eluted from both K b subsets 
sensitized Kb-transfected T2 ceils expressing "peptide empty" K b for lysis to a similar extent 
by allo-CTL clones, indicating  that  relevant endogenous peptide antigens  are not limiting  in 
the Ly-mll § K b subset. The major distinction  identified between the two K b subsets is that 
they differ substantially in their degree of N-linked glycosylation, with the Ly-mll + subset con- 
taining  K b molecules  with  larger  and  more  complex  carbohydrate  modifications  than  the 
M1/42  high subset.  The differences in  glycosylation may explain  the functional differences ob- 
served between the two K b subsets.  It is therefore possible that  some forms of glycosylation 
on class I molecules interfere with TCP~ recognition and may limit CD8 + T cell responses, per- 
haps under  circumstances where peptide antigen  is limiting. 
C 
lass I MHC-restricted CD8 § CTL recognize a complex 
of MHC class I heavy chain, 32-microglobnlin (32m) t 
and  a peptide antigen.  An  allo-specific  CD8 §  CTL clone 
usually recognizes complexes of allo-class  I and one or only 
a small number of specific endogenously processed peptide(s) 
(1, 2). Collectively, a population of allo-specific CTL respond 
to allo-class  I and a diverse array of endogenous bound pep- 
tides (1, 2). Activation of CD8 § CTL requires MHC com- 
plex interaction  with the TCR,  and usually its coreceptor 
CD8  that  provides cosignaling  functions  (3-5). 
We have shown previously that immobilized purified class 
I  MHC  alloantigens  serve  to  trigger  several  allo-specific 
CD8 +  CTL  clones  and  therefore  class  I  alloantigen  is  a 
necessary and sufficient ligand for CTL adhesion and activa- 
tion ofa degranulation response (3). When class I is the only 
ligand  on the surface,  the CTL adhesion  and response de- 
pends on the participation  of both TCR and CD8 (4).  A1- 
1  Abbreviations used in this  paper: B2m, 32-microglobulin; DOC, deoxycho- 
late; Endo H, Endoglycosidase  H; NANAse, neuraminidase; PL, poly- 
N-acetyllactosamine; SE, serine esterase. 
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though specific bound endogenous peptides are required for 
aUo-CTL recognition, it is not known whether all potential 
forms of a given allo-class  I molecule are capable of serving 
as alloantigens  even when bound with relevant peptide(s). 
It has been demonstrated that the same dass I allele prod- 
uct can be expressed at the cell surface with heterogeneous 
N-linked carbohydrates (6-8). Although glycosylation on cer- 
tain murine class I molecules is not required for allo-CTL 
recognition (9, 10), it is unclear what influence the complexity 
of N-linked glycosylation on class I may have on CTL recog- 
nition,  although cell surface sialylation, possibly on class I, 
influences class  I  antigen  presentation  (11). 
In the present  study,  we isolated and characterized  two 
cell surface subsets of murine H-2 K b from detergent lysates 
of EL4 and other H-2 Kb-bearing  cells.  These K b subsets 
were found to differ serologically;  although both subsets share 
similar Y3 reactivity, one subset is Ly-m11 § and the other 
is predominantly reactive with the M1/42 antibody. The two 
K b subsets differed dramatically in their abilities to serve as 
TCR ligands for allo-specific  CTL adhesion, and transmem- 
brahe signaling as measured by alloantigen-specific degranu- 
lation.  The  two  K b subsets  also  varied  in  their  N-linked 
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ences  observed between  the two K b subsets  is discussed. 
Materials and Methods 
mAbs.  M1/42,  a rat anti-mouse mAb (IgG2~) reactive with 
most H-2 class I antigens (12) was obtained from American Type 
Culture  Collection  (ATCC;  Rockville,  MD).  The  Kb-specific 
mAbs used in this study were: Y3  (IgG2b) (13); B8-24-3  (IgG1) 
(14); AF6 (IgG2~) (15) obtained from ATCC; and 5F1  (IgGzb), a 
gift from Dr. L. Sherman (Research Institute Scripps  Clinic, La 
Jolla, CA) (16); and 100-30 (IgG2b), a gift from Dr. U. Hammer- 
ling (Memorial Sloan-Kettering Cancer Center, New York) (17). 
The  S19.8  (IgG2b),  an  anti-mouse  32m  (Ly-mll  epitope)  mAb 
which specifically recognizes 32m of b strain mice (18), was also 
a gift from Dr. U. Hammerling. A hamster mAb that recognizes 
CD3e,  145-2Cll  (19), was obtained from ATCC. The anti-CD8 
mAb, 3.168  (IgM) (20),  was a gift from Dr. A. O'Rourke (Re- 
search  Institute Scripps  Clinic,  La Jolla,  CA). 
Enzymes.  Recombinant Streptomyces plicatus Endoglycosidase  H 
(Endo H) was purchased from Boehringer Mannheim Biochemica 
and Endoglycosidase  F (Endo F) purified from Flavobacterium menin- 
gosepticum was purchased from Du Pont Company (Wilmington, 
DE). Type V neuraminidase (NANAse) from Clostridium  perfringens 
was purchased from Sigma Immunochemicals (St.  Louis,  MO). 
Tumor Cell Lines.  The murine T cell lymphoma cell line EL4 
(H-2  b) was obtained from ATCC. ANA-1, a macrophage cell line 
of C57BL/6 origin (21), was a gift from Dr. M. Belosevic  (Uni- 
versity of Alberta,  Edmonton,  Canada).  The murine pre-B cell 
line,  R8  (H-2  b'~) (22)  was provided by Dr.  R.  Zeff (University 
of Connecticut,  Farmington,  CT).  The  human  transfected cell 
line T2K  b (23) was a gift from Dr. P Cresswell (Yale University, 
New Haven, CT). 
Cloned CTL.  The K b allo-specific  CTL clones  11,  35,  6,  13 
and AB.1 have been well documented (3, 24).  The D d allo-specific 
CTL clone 10/1 was derived from C57BL/6  spleen  cells primed 
in vitro with irradiated (3,000 rad) Balb/c spleen cells and cloned 
1 wk later by limiting dilution in the presence of 5 % Con A super- 
natant. All the allo CTL clones were maintained as previously de- 
scribed  (3,  24). 
Isolation and ELISA  of H-2  K b Subsets.  The  H-2  K b was 
purified from various cell lines by immunoaffinity chromatography 
as described (25)  with modifications.  EL4 cells were propagated 
in vivo as ascites, while the ANA-1 and R8 cells were grown in 
5%o  FCS-DMEM.  Detergent  lysates  from  1.0-1.5  x  101~ cells 
were passed over a Y3 affinity column preceded by a Sepharose 4B 
precolumn. Two sequential elutions were performed immediately 
after the column washes (25). The first elution buffer, 0.5% DOC, 
0.65 M NaC1, 10 mM Tris, pH 8.3-8.5, has been described previ- 
ously (25).  Following elution with this buffer, a second elution 
is done using a buffer of higher pH: 0.5% DOC, 0.15 M  NaC1, 
15 mM Na2CO3,  pH 10.5. For some preparations, fractions of the 
first (pH 8.5) or second (pH 10.5) elution showing strong ELISA 
reactivity with  the  Kb-specific  mAb Y3  as  first  antibody were 
separately pooled and stored at  -20~  Direct ELISA of affinity- 
purified H-2 K b was performed as previously described (25).  Im- 
munoaffinity purifications of K k and I-E  d, I-A  a molecules used in 
this study were as described previously (25).  For monitoring the 
purification of cell surface K b molecules, 20  x  106 EL4 cells were 
125I-labeled by lactoperoxidase/oxidase-catalyzed iodination  (26), 
and their lysates  added to the routine EL4 preparation as tracer. 
Assay of CTL Binding and Degranulation.  CTL adhesion and 
degranulation responses  to purified class I and coimmobilized pro- 
teins has been previously described in detail (4).  1-2  x  10  s SlCr- 
labeled  CTL were incubated for 4 h at 37~  on protein-bearing 
plate wells and unbound cells were then removed. In experiments 
employing fluid phase anti-CD3 mAb, the antibody was added to 
the cells in suspension and the cells immediately placed into the 
well. The anti-CD8 mAb blocking experiment was performed by 
incubating CTL with the antibody at the indicated concentration 
at room temperature for 30 min. Cell binding was calculated  as: 
percent cell bound =  100  x  [(cpm bound)/(total cpm-spontaneous 
cpm)]. Experiments were done in triplicate for each condition un- 
less  specified. 
Degranulation by the CTL was assessed by measuring the serine 
esterase (SE) activity released into the medium by the N'-benzyl- 
oxycarbonyl-t-lysine thiobenzyl ester assay as described  (3, 4). De- 
termination of CTL binding and SE release was done simultane- 
ously from the same wells.  The SE release  assay was allowed to 
proceed for 20 min and OD40snm was determined. SE release is ex- 
pressed as AOD40snm =  OD40s,m(CTL  +  immobilized class I)  - 
OD40snm(CTL +  wells blocked with 2% FCS in PBS). Determi- 
nations were done in triplicate for each condition unless specified. 
Acid Extraction of Peptides  from Purified K b Subsets.  Peptides  as- 
sociated  with purified K b were extracted by TFA (27).  Peak frac- 
tions of pH 8.5-eluted (Ly-mll +) and pH 10.5-eluted  (M1/42 high) 
subsets  were separately pooled.  The pools were serially  diluted, 
ELISA using Y3 as first antibody was performed and equivalent 
amounts of Y3-reactive K b (defined  as equal value of ELISA OD 
value  ￿  sample volume) were subjected to acid extraction with 
a final concentration of 0.05% TFA. The samples were centrifuged 
in Centricon-10 microconcentrators, filtrates  (<104 mol wt) freeze 
dried,  resuspended in 0.1%  TFA-H20,  and separated on Cls re- 
verse phase HPLC. Both pH 8.5 and 10.5 elution buffers were sub- 
jected to identical treatment in parallel  as mock-treated controls. 
HPLC Separation of Extracted Peptides.  Peptide were separated 
on  a  narrow-bore  Cls  (2  mmx  25  cm) column  set  up  on  a 
Beckman System Gold HPLC. The solvents were A: 0.1% TFA- 
H20; B: 0.09% TFA, 80% acetonitrile, 20% H20. A linear gra- 
dient of acetonitrile was applied with the gradient rate of 0.8% 
acetonitrile/min and a flow rate of 0.2 ml/min.  Fractions corre- 
sponding to the 20-50% acetonitrile gradient were pooled, lyophi- 
lized, washed, and reconstituted in 50/A D-PBS for the sensitiza- 
tion of T2K  b cells for allo-CTL lysis. 
Cytotoxicity Assay.  Peptides  extracted from purified K b were 
tested for their  ability to  sensitize T2K  b cells  for lysis by allo- 
specific CTL clones.  51Cr-labeled T2K  b cells were resuspended in 
assay medium at a density of 3  ￿  106/ml.  A volume of 50 #1 of 
the cell suspension was incubated with various dilutions of pep- 
tides isolated from purified K b subsets at 37~  for 45 rain. Then 
the T2K  b cells were diluted  to  1  x  105/ml  with assay medium 
and 100 gd was incubated with various CTL clones at a 5:1 E/T 
ratio for 5 h in V-bottom plates in triplicate.  Percent specific 51Cr 
release was calculated  as: [(experimental release  -  spontaneous re- 
lease)/(maximum release  -  spontaneous release)]  x  100. Results 
are expressed  as mean  %  specific 51Cr release  _  SD. 
SDS-PAGE.  The purified  H-2 K b subsets were analyzed by 
10% or 12.5% SDS-PAGE  under reducing conditions (28).  Gels 
were stained by Coomassie blue. Autoradiography was also carried 
out to visualize the  12SI-labeled proteins in  the gel. 
Endo  H,  Endo  F,, and NANAse  Treatment of Purified H-2 K b 
Subsets.  The isolated H-2 K b proteins were acetone precipitated 
in the presence of BSA as carrier,  and the precipitates were dis- 
solved in 50/zl of their respective enzyme incubation buffers (29). 
Samples were incubated with 3-6 mU of Endo H  or 0.5-1.0 U 
of Endo F as previously described (10, 29).  NANAse treatment 
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for 4 h (11). 
Results 
Isolation of Two Serologically Distinct K b Subsets from H-2 L 
expressing Cell Lines.  Standard protocols for immunoaffinity 
purification of murine class I MHC molecules from cell de- 
tergent lysates typically involve elution of the antigens from 
the affinity column at pH 8.5 in 0.5% DOC detergent (25, 
30).  However, we have found that not all K b is eluted from 
a Y3 mAb column using standard elution conditions at pH 
8.5 (data not shown). If an elution buffer ofpH 10.5 is used 
immediately following the pH 8.5 elution buffer, a second 
immunoreactive K b peak can be isolated from several H-2  b- 
expressing cell lines as determined by solid phase ELISA using 
Y3 as first antibody (Fig.  1, data not shown). We also ana- 
lyzed individual eluted fractions by ELISA with the S19.8 
mAb which recognizes the Ly-mll epitope on ~2m when 
associated with K b (22).  S19.8-reactive material eluted coin- 
cidently with the first Y3-reactive peak (peak 1), but not the 
second (peak  2),  indicating that two serologically distinct 
K b subsets can be separately isolated from H-2b-expressing 
cells  using  a  Y3  affinity column  (Fig.  1).  The  two  K b 
subsets can be isolated from various cell lineages  including 
T cell lines e.g., EL4 (Fig. 1 a), macrophage/monocyte lines, 
e.g., ANA-1 (Fig.  1 b) and also from a pre-B  cell line, R8 
(Fig.  1 c). To further characterize  the two K b subsets, both 
serologically  and functionally, we have gone on to use K b 
subsets isolated from EL4 because of the greater yield of both 
subsets  from this cell line. 
ELISA Reactivity of Isolated H-2 K b Subsets.  The strongly 
Y3-reactive fractions of peak 1 and peak 2 isolated from EL4 
cells were pooled separately and ELISA reactivity with sev- 
eral Kb-reactive antibodies  was determined. From the ELISA 
results, the mAbs can be grouped into three categories (Table 
1). The first group includes Y3, 100-30, 5F1, and AF6 which 
react  strongly to both K b subsets.  Y3 is reported to recog- 
nize K b irrespective of association with 32m or specific pep- 
tides (31, 32).  The Y3 reactivity by ELISA is high for the 
pH 8.5- and 10.5-eluted  K  b (Table 1). In contrast to Y3, the 
reactivity of 5F1 with K b is dependent on associated pep- 
tide (31). Reactivity of this mAb is found with both K b 
subsets at comparable levels, suggesting that both K  b subsets 
have bound peptides.  Furthermore, both subsets  also react 
with 100-30 and AF6 which recognize peptide-dependent 
conformational epitopes of K b (33). 
A second mAb group only includes $19.8. This antibody 
recognizes K  b associated with the 32m expressed by C57BL/6 
and related mouse strains and a bound peptide (18, 22) and 
reacts exclusively with peak 1, but not the peak 2 subset of 
K b and therefore readily discriminates between these two 
subsets. 
A  third  group includes M1/42  and B8-24-3  which are 
strongly reactive with peak 2, but react weakly with peak 
1. M1/42 mAb is also strongly reactive with peak 2 of both 
ANA-1 and R8 cells but weakly reactive with peak 1 (data 
not shown).  Since M1/42 mAb reactivity requires  mouse 
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Isolation  of two serologically  distinct  K  b subsets from H-2K  b 
expression cells. K  b molecules  were isolated from (a) EL4, (b) ANA-1, and 
(c) R8 cells by Y3 mAb immunoaffanity  chromatography.  Elutions  of K  b 
from  Y3 mAb column  were  performed  by sequential  application  of pH 8.5 
and 10.5 buffers. Open and solid arrows indicate  the start of pH 8.5 and 
10.5 elutions, respectively. Each fraction (1:20 dilution) was assayed  for 
Y3 (Fq) and S19.8 (Ly-mll)  (0) mAb reactivity  by solid-phase  ELISA. 
Purified  mAb Y3 (2.1 mg/ml)  was diluted 1:500, and S19.8 culture super- 
natant was at a 1:4 dilution. Results are expressed as an average of 
OD49onm  of duplicate wells. 
32m to be  associated  with murine class I  molecules (34), 
these results demonstrate that peak 2 contains class I mole- 
cules with associated murine ~2m. Therefore both isolated 
subsets contain K b associated with murine 32m. The B8-24- 
3 mAb recognizes a conformational epitope dependent on 
/32m and peptide association, providing further evidence that 
peak 2 contains peptide-MHC complexes. Based on the sero- 
logical characteristics  of the two K b subsets determined by 
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EL4  Cells* 
Peak  1  Peak 2 
mAb*  (pH 8.5  elution)  (pH  10.5  elution) 
Y3  0.861  +  0.051s  0.885  _+  0.038 
5F1  0.361  _+  0.028  0.488  _+  0.024 
100-30  0.590  _+  0.050  0.842  _+  0.071 
AF6  0.662  ___  0.056  0.722  _+  0.091 
$19.8 (Ly-m11)  0.852  _+  0.054  0.005  _+  0.012 
M1/42  0.033  +  0.016  0.917  _+  0.026 
B8-24-3  0.153  _+  0.023  0.812  _+  0.083 
* ELISA reactivity of isolated EL4 K  b subsets to various mAbs was de- 
termined. From a representative preparation, ELISA  peak fractions of pH 
8.5- and pH 10.5-eluted Kb were pooled separately, diluted 1:20 into 
D-PBS for all assays. 
* First antibody used in ELISA assay: Y3 (2.1 mg/ml) and M1/42 (1.5 
mg/ml) were purified and diluted 1:500 in 2% FCS-PBS; 5F1 was used 
as ascites at a 1:100 dilution; 100-30, AF6, B8-24-3 and $19.8 (Ly-m11) 
were used as culture supernatants in 5%  FCS-RPMI at 1:4 dilution. 
Results were expressed as mean  OD490nm +  SD of triplicate wells. 
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solid-phase ELISA, we operationally define the pH 8.5-eluted 
K b subset as Ly-m11 + and the subsequent pH 10.5-eluted K b 
subset  as  M1/42 high. 
Allo-specific  CTL  Clones  Bind  and  Are  Triggered  by  the 
M1/42hir ~ but Not the Ly-mI1 + K b Subset.  Due to the sero- 
logical differences  detected in the previous ELISA studies (Table 
1) between the two K b subsets, we tested the ability of each 
isolated  subset  immobilized  on  solid-phase  to  stimulate 
antigen-specific degranulation by K b allo-specific CTL clones 
(3).  We found that the M1/42hig  h K b subset  stimulated de- 
granulation of allo-specific CTL clones as measured by SE 
release,  whereas  the Ly-m11 §  K b subset  did not (Fig.  2 a). 
The degranulation response of the three CTL clones, elicited 
by the M1/42 high K b subset, is comparable to that triggered 
by Kb-bearing EL4 allogeneic target  cells  (3,  and data not 
shown). 
When  binding  of the  CTL  clones  to  immobilized  Ly- 
re11 +  and  M1/42hig  h  K b  subsets  was  examined,  similar 
results to the SE release assay were obtained (Fig. 2 b). Sub- 
stantial binding,  40-60%  of the input  CTL, was observed 
to the immobilized M1/42 high K b subset.  In contrast,  only 
minimal binding above background, 1-5%, could be detected 
with the immobilized Ly-m11 + K b subset.  Equivalent den- 
sities  of Y3-reactive  K b of both  subsets  were  used  in  the 
binding and SE assays, while the contrasting $19.8 and M1/42 
reactivity of each subset was also confirmed by ELISA (Fig. 
2 c).  Additional allo-specific CTL clones 35 and  13 (3, 24), 
also displayed strong adhesion and response to the M1/42hig  h 
K b but no adhesion or response to the Ly-m11 + K b subset 
of immunoaffinity  purified  K b  on  solid-phase  (data  not 
shown).  Taken together,  the results  in Fig.  2  suggest  that 
there  are  functional  differences between  the  Ly-m11 §  and 
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Figure  2.  Allo-specific CTL  clones bind  and are  triggered by the 
M1/42hig  h, but not Ly-m11  + K  b subset. Antigen-specific SE release (a) 
and binding (b) of three K  b allo-specific CTL clones in response to im- 
mobilized Ly-m11  + (solid bar) and M1/42hig  h (open bar) K  b subsets were 
determined. 2 x  105 of each CTL clone were added to each well and in- 
cubated for 4 h. Results are expressed as mean +  SD. The same Ly-m11  + 
(solid bar ) and M1/42hig  h (open bar) K  b subsets were assayed for their im- 
munoreactivity with Y3, M1/42 and $19.8 mAbs in parallel by ELISA 
(c) at a density identical to that used in the above CTL binding and SE 
release experiments. Results are expressed as mean OD490,m -+  SD. 
M1/42  high K b subsets; the allo-CTL bind and degranulate in 
response to the M1/42hig  h K b subset,  but  not the Ly-m11 + 
K b subset. 
Dose-response Relationship  of CTL Recognition  of K b Subsets. 
The Ly-mll + and M1/42hig  h K b subsets were serially diluted 
and immobilized  separately on solid-phase and  assayed for 
binding and stimulation of degranulation of allo-specific CTL 
clone  11.  At  the  highest  density  shown,  both  K b subsets 
reached equivalent saturating densities as detected by solid- 
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sponse  to the M1/42hig  h K b subset shows a titration curve 
that includes a threshold density for stimulation and rises 
to a maximal response at saturating density (Fig. 3). Adhe- 
sion of the CTL clones to the immobilized M1/42hig  h K b 
subset closely paralleled the dose-response curve of SE release. 
In  contrast,  the Lyom11  +  K b subset  could not be bound 
or stimulate the CTL clone at any density, even when the 
Ly-m11 + K  b subset is at a high and saturating density (Fig. 
3).  Other K b allo-specific  CTL clones including clone 35 
and AB.1  also were bound to and were stimulated by the 
M1/42  bigh K b subset,  but  did not bind or respond to the 
Ly-mll + K  b subset (data not shown). 
The Ly-mll + Subset K s Molecules Do Not Inhibit CTL Rec- 
ognition of the M1/42hie  h K s Subset.  We tested the possibility 
that the Ly-m11 + K  b subset contained inhibitory activities 
that could prevent or interfere with recognition of K b al- 
loantigen by CTL. As expected, plate wells immobilized with 
the Ly-mll + K b subset did not stimulate the CTL, whereas 
the M1/42 high K b subset did stimulate significant antigen- 
specific CTL degranulation (Fig.  4).  Coimmobilization of 
the nonstimulatory Ly-m11 + K b subset with the M1/42  high 
K b did not inhibit the antigen-specific CTL degranulation 
response  to the M1/42hig  h K b subset  (Fig.  4).  Since the Ly- 
mll +  K  b  subset  does  not  inhibit  CTL  recognition  of 
M1/42hig  h K b subset, it is therefore unlikely that inhibitory 
activities  are  present  within the Lyom11  +  K  b subset  that 
could readily explain the lack of response to the Ly-m11 + 
K b subset by allo-specific  CTL. 
The M1/42hig  h but Not  the  Ly-m11 + K b Subset Serves  as a 
CTL  TCR  Ligand.  The failure of the Ly-m11 + K b subset 
to trigger allo-CTL could be due to an inability to engage 
and trigger TCK and/or CD8 molecules on the CTLs (4). 
We have demonstrated that when a suboptimal density of 
purified class I alloantigen is not sufficient to trigger a full 
CTL response,  it can  still activate  via TCR engagement, 
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Figure  3.  Dose-response relationship of CTL recognition of K b subsets. 
Both  K b  subsets  were  serially  diluted  separately  and  immobilized  on 
plastic.  10  s clone 11 CTL were added and incubated for 4  h.  Results of 
both CTL binding and SE release were averages of duplicate wells.  The 
variation was less than  10%  between wells. 
Figure  4.  The Ly-m11+  K b sub- 
set does not inhibit recognition of 
the M1/42hig  h K b subset by an allo- 
specific CTL clone. Two K s subsets 
containing an equivalent amount of 
Y3-reactive  K b  were  diluted  1:20 
separately in D-PBS  and immobi- 
lized individually on the plate. For 
the  mixing  experiment,  both  K b 
subsets were diluted together into 
D-PBS in which each K b subset is 
1:20 diluted, and coated on the plate. 
Clone  11  SE  release  triggered  by 
Ly-m11 +,  M1/42hig  h,  or  the mix- 
ture  of both  K b  subsets  was  de- 
termined. 
"avidity enhanced" CD8 binding to coimmobilized non-Ag 
class I molecules (4), resulting in enhanced CTL binding and 
degranulation response  (4).  If the Ly-mll §  K b subset  can 
serve  as a TCR ligand, it  should trigger enhanced CD8- 
dependent CTL binding and possibly a degranulation response 
when coimmobilized with non-Ag class I molecules. 
When the Ly-m11 + K b (possible TCR ligand) was coim- 
mobilized with K k (non-Ag class I, CD8 ligand) we could 
not detect TCK-triggered CTL binding or degranulation of 
CTL clone 11 (Fig. 5, a and b). At no density could the Ly- 
mll §  K b subset  trigger clone  11  CTL with  or  without 
coimmobilization with nonoAg class I (data not shown). In 
contrast, although the M1/42hi~  h K b subset  at a suboptimal 
density was not sufficient to trigger the allo-CTL clone 11 
to bind and degranulate alone, it triggered clone 11 to bind 
to coimmobilized K k and degranulate, indicating that the 
M1/42hig  h K  b subset serves as a TCR ligand (Fig.  5, a and 
b).  The  TCR-triggered  binding  or  degranulation of the 
CD8 + CTL clone was not observed when either K b subset 
was coimmobilized with class II MHC control molecules (Fig. 
5, a and b).  These results suggest that the immunoaffinity 
purified M1/42hig  h K b subset serves as a TCR ligand, up- 
regulating CD8 adhesion and signaling function, but the Ly- 
mll + K  b subset does not serve this function for clone 11 and 
all of a number of other K b alloantigen-specific  CTL clones 
tested (Fig.  5 and data not shown). 
Both  the  Ly-m11 + and M1/42hlg  h K b Subsets  Are  CD8  Li- 
gands.  Since  the  preceding results  showed that  only the 
M1/42hig  h K  b subset could serve as a TCR ligand, we sought 
to determine whether either subset  could serve  as a CD8 
ligand. It has been shown that soluble anti-TCR antibody 
activates adhesion of CD8 + CTL to class I, but not class II 
MHC proteins (35). The adhesion is mediated by CD8, since 
it is effectively  inhibited by anti-CD8 antibody (35). When 
the D d allo-specific CTL clone 10/1 was treated with soluble 
anti-CD3 antibody, 145-2Cll, it bound and degranulated in 
response  to immobilized non-Ag class I (Kk), but not class 
II (bA  d) proteins (Fig. 6, a and b). A substantial and similar 
degree of TCR-activated CTL binding was observed for both 
immobilized Ly-mll + and M1/42  high K b subsets  (Fig. 6 a), 
and CTL binding to both K b subsets  could be effectively 
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Figure  5.  The M1/42hig  h, but not the Ly-mll + K b subset, can serve 
as  a  TCR  ligand.  Both  the Ly-m11 +  and M1/42hig  h K b subsets (0.07 
#g/well) were separately immobilized alone, or coimmobilized with H-2 
K k (0.15  /~g/well) or I-E  d (0.21  #g/well)  as indicated.  The wells were 
blocked with 2% FCS in D-PBS. Clone 11 CTL were added to wells at 
1.5  x  105 cell/well, incubated for 4 h  at 37~  and binding (a)  and SE 
release (b) determined. Data were expressed as the mean of triplicate wells. 
blocked by anti-CD8 mAb (Fig. 6 a, inset). In addition, strong 
degranulation responses  to  immobilized K b subsets  were 
observed,  with  the  Ly-m11 +  subset  providing  somewhat 
stronger CD8 costimulation than the M1/42hig  h K b subset 
(Fig. 6 b). From these observations, we concluded that both 
K b subsets  can serve as CD8 ligands, and the Ly-mll + K b 
subset may possibly deliver  more efficient  signals  through 
CD8 to activate CTL degranulation. 
Figure  6.  Both the Ly-mll+  and M1/42hig  h K b subsets can serve as 
CD8 ligands. The Ly-m11 + and M1/42hig  h K b subsets (both at a density 
of 0.15 #g/well),  H-2 K k (0.16/~g/well),  I-A  d (0.20/xg/well),  or BSA 
(100 #g/well) were separately immobilized on the wells as indicated, and 
blocked with 2% FCS in D-PBS. The D d allo-specific CTL clone, 10/1, 
was loaded  into  the wells at  1.0  x  10  s cell/well.  Immediately before 
loading, clone 10/1 cells were treated with 0.25 p.g/ml 2Cll mAb (solid 
bar ), or without antibody treatment (open bar ). CTL clone 10/1 binding 
(a) and SE release (b) were determined. In a separate experiment, the effect 
of anti-CD8 mAb on clone 10/1 binding was tested (a, inset).  Clone 10/1 
were incubated at room temperature with 3.168 mAb at  1:100 dilution 
of ascites for 30 min before the addition of 2Cll mAb. Clone 10/1 binding 
in the absence of 2Cll was 3.5%  (not shown). In the presence of 2Cll 
mAb, clone 10/1 adhesion with (hatched bar) or without (solid bar)  3.168 
mAb treatment was determined. All data were expressed as the mean of 
triplicate wells.  Binding and SE release of clone 10/1  in the absence of 
mAb 2Cll in the BSA-coated wells were determined as background and 
subtracted from the experimental groups. 
The Lack of TCR Recognition of Ly-mll + K b Subset Is Not 
Due to the Absence of  Relevant Bound Endogenous Peptides.  That 
most allo-specific  CTL recognize an allo-class I molecule bound 
with specific endogenously processed peptide(s)  (1, 2) sug- 
gested the possibility that the functional differences exhibited 
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differences in the composition of endogenous peptides bound 
by the two K b subsets. To test this possibility, we acid-eluted 
endogenous  peptides  from equivalent  amounts  of the  two 
isolated K b subsets, based on their Y3 ELISA reactivity, and 
assayed them for the ability to sensitize T2K  b cells for lysis 
by Kb-specific allo-CTL (1,  36).  The T2K  b cells are believed 
to  express  peptide  "empty"  K b  molecules  and  they  are 
efficient at binding and presenting exogenous peptide antigens 
(23).  Lysis of T2K  b cells by allo-specific CTL clone 35  and 
clone  11 is dependent  on endogenous  peptides  eluted from 
isolated K b (Fig.  7, a  and  b). Peptides  eluted from both Ly- 
mll + and M1/42hig h K b subsets sensitized T2K  b for lysis to 
comparable levels, by clone 35 (Fig. 7 a) and clone 11 (Fig. 7 b). 
Titration  of the eluted  peptides  from the K b subsets  for 
the T2K  b sensitization  indicates  that  the yields of the rele- 
vant  peptides  mediating  allorecognition  for clone  11  (Fig. 
7  b) and clone 35  (data  not  shown)  are similar  for the Ly- 
re11 + and M1/42hig  h K b subsets.  From these results, we con- 
clude that the relevant peptides for recognition by the allo- 
specific CTL  clones  are  associated with  both  the Ly-mll § 
and M1/42hig  h K b subsets.  Furthermore,  the appropriate pep- 
tides  do  not  appear  to be limiting  in  the  Ly-m11 +  subset, 
hence it is unlikely that associated peptides provide an expla- 
nation  for the differences in functional  activities of the Lyo 
mll +  and  M1/42hig h K b subsets. 
The  Ly-mll + and  M1/42hie h K b Subsets  Differ  in  Their 
N-Linked Glycosylation.  We attempted to determine the bio- 
chemical basis for the observed serological and functional differ- 
ences between the two K b subsets.  The SDS-PAGE analysis 
with  Coomassie blue  staining  revealed  a  47-kD  K b heavy 
chain  (Fig.  8  a,  lane 2,  solid arrow) and  a  12-kD/~2m  (not 
shown) in the M1/42 high K b subset.  Two major bands were 
seen in the Ly-m11 + K b subset;  one band at 51  kD  (Fig.  8 
a,  lane  1,  barbed arrow) with  a barely visible smear  on  top 
and  another  band  at  43  kD  (Fig.  8  a,  lane  1,  open arrow). 
The identity of the 43-kD band is unclear, however it is Endo 
H  and Endo F insensitive (data not shown)  and is therefore 
likely to be a contaminant such as actin, which has been seen 
in class I  immunoprecipitations  (29,  37).  For  the Ly-m11 + 
K b subset, the/~2m is less readily seen in Coomassie staining, 
but  is  visualized  by  silver staining  (data  not  shown). 
When the K b subsets were purified from EL4 cells labeled 
with  125I and  visualized  by autoradiography,  a  clear  differ- 
ence  in  molecular  mass  between  the  two  K b  subsets  was 
again observed.  The M1/42his h K b is a 47-kD band (Fig.  8 
b, lane 4);  in contrast,  the Ly-m11 +  K b subset  was visual- 
ized as a broad 51-56-kD band likely to be made up of mul- 
tiple closely migrating bands (Fig.  8 b, lane 1 ). This 51-56- 
kD broad band most probably includes  the 51-kD band on 
the Coomassie blue staining gel in Fig.  8 a. Since both EL4 
K b subsets  were labeled by  125I, we  presume  that  they  are 
both cell surface forms of K b. Higher molecular mass H-2K  b 
Figure  7.  The lack of TCR recognition of Ly-mll § K  b is not due to 
a lack of relevant bound endogenous peptides. (a) Clone 35 killing of slCr- 
labeled T2K  b cells sensitized with 10/xl of peptides isolated from both 
K  b subsets with equivalent Y3-reactivity. (b) Different volumes of eluted 
peptides isolated from Ly-m11  + or M1/42hig  h K  b subsets were used to sen- 
sitize T2K  b cells for killing by a K  b allo-specific  CTL clone, 11. Percent 
specific lysis is expressed as the mean of triplicate wells. 
Figure  8.  Biochemical  analysis of the Ly-mll + and M1/42hig  h K  b sub- 
sets. (a) SDS-PAGE  analysis of the purified K  b subsets. Equivalent amounts 
of the Y3-reactive Ly-mll + (lane 1 ) and M1/42hig  h (lane 2) K  b subsets 
were analyzed on 10% SDS-PAGE  with Coomassie blue staining. Molec- 
ular mass markers are shown on the right. (b) Endo H and Endo F treat- 
ment of the K  b subsets. Both K  b subsets were treated with 6 mU Endo 
H (H) or 0.8 U Endo F (F) or mock treated (-) at 37~  for 20 h, ana- 
lyzed on 10% SDS-PAGE, and visualized by autoradiography. Molecular 
mass markers  are as shown. (c) NANAse treatment of the K  b subsets. The 
K  b subsets were treated with 0.5 U NANAse (+) or mock treated (-) 
at 37~  for 4 h, analyzed on 12.5% SDS-PAGE and visualized by auto- 
radiography. 
1779  Shen and Kane molecules with a similar migration  and banding pattern to 
that  observed  in  the  EL4  Ly-m11 §  K b subset  have  been 
identified  in  immunoaffinity  purified  preparations  of K b 
from the B/6 murine leukemia cell line RBL-5 and may rep- 
resent  similar  K b species  (38,  39). 
Since  the  apparent  differences  in  migration  of the  Ly  o 
mll § and M1/42hig h K b subsets on SDS-PAGE could be due 
to differences in glycosylation, we performed Endo H, Endo 
F, and NANAse treatment  of both K b subsets. After Endo 
F treatment, both the 51-56-kD broad band in the Ly-m11 + 
K b subset  (Fig.  8  b,  lane  1)  and  the  47-kD  band  in  the 
M1/42h~g  h K b subset (Fig. 8 b, lane 4 ) shifted in mobility to 
a position corresponding to 40 kD (Fig. 8 b, lanes 3 and 6). 
This result suggests that:  (a) both K b subsets are N-linked 
glycosylated, and (b) their peptide backbones are of the same 
or very similar size, making it very unlikely that the differ- 
ence in  molecular  mass  of the  two  K b subsets  is  due  to 
differential  splicing (40). Both subsets were found to be resis- 
tant  to Endo H  treatment  (Fig.  8  b, lanes  2  and 5),  indi- 
cating that  the N-linked carbohydrates on both subsets are 
of a mature or complex form.  Upon NANAse treatment, 
the 51-56-kD band of the Ly-m11 + K b subset shifted only 
very slightly towards the gel bottom (Fig.  8 c, lane 2). This 
suggests either that sialylation is not the major factor respon- 
sible for the mobility difference between the Ly-mll + and 
M1/42hig h K b subsets,  or  there exist  sialic  acid-containing 
carbohydrates on the Ly-mll § K b subset that  are resistant 
to NANAse treatment  (41).  Occasionally, upon longer ex- 
posure, we see a faint 47-kD band that corresponds to the 
size  of the  M1/42hig h K b band  in  the  Ly-mll +  K b subset 
(Fig.  8 c) which may or may not be Ly-mll reactive or pos- 
sibly represents some contaminating  M1/42-reactive K b. In 
summary,  the Ly-mll + and M1/42hig h K b subsets differ in 
their N-linked glycosylation in addition to their serological 
and functional differences.  The observed variance in glycosy- 
lation between the two K b subsets may be responsible for 
their  observed functional  differences. 
Discussion 
We have demonstrated  herein  that  two immunoaffinity 
purified K b subsets differ in their serology, glycosylation and 
ability to trigger allo-specific CTL.  The serological charac- 
teristics of the two K b subsets (Table 1) indicate that  each 
contains K b heavy chain associated with 32m as the epitopes 
recognized by $19.8,  M1/42 and AF6 mAbs are dependent 
on class I heavy chain association with murine 32m (22, 31, 
34).  Furthermore,  since  both  K b subsets are  reactive with 
several mAbs that are dependent on peptide association with 
K b  (31-33),  both  subsets  contain  endogenous  peptides. 
Complexes of class I MHC molecules with different endoge- 
nous peptides can be distinguished from each other by allo- 
antibodies (27, 31-33). These serologically defined differences 
may be due, in part, to subtle peptide-dependent conforma- 
tional variations in the class I heavy chain (31),  or to differ- 
ences in the size of exposed peptide side chains that may affect 
antibody binding (33). The serological differences between 
the two K b subsets could suggest  that  certain  endogenous 
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peptides may be predominantly bound to one or another K b 
subset. Despite the observed serological differences,  relevant 
peptides could be extracted from both K b subsets with com- 
parable  yield  for  sensitizing  T2K  b  cells  for  alloantigen- 
specific CTL lysis. These results indicate that the functional 
differences between the two K b subsets are not likely to be 
due to the absence or insufficiency of the relevant peptide(s) 
bound with  K b. 
Given that both K b subsets contain sufficient  amounts of 
relevant peptides for allo-CTL  stimulation,  we considered 
a second possibility for why the Ly-m11 + K b subset did not 
trigger the CTL clones;  namely the Ly-m11 + K b subset con- 
tains peptide-K  b complexes that are TCR antagonists,  similar 
to what has been reported for complexes of MHC molecules 
and certain synthetic peptide antigen analogues (42, 43). How- 
ever, our results indicate that the Ly-mll + K b subset is un- 
able to inhibit the binding and response of the allo-specific 
CTI, dones when coimmobilized with stimulator),  M1/42  high 
K b subset molecules,  suggesting that the Ly-m11 § K b subset 
does not apparently contain strongly antagonistic activities. 
We observed a significant difference in molecular mass of 
the  two K b subsets,  with  the  M1/42hig h K b subset being 
,047 kD and  the Ly-mll + K b subset ranging  from 51-56 
kD. Murine  class I at the higher  molecular mass has been 
occasionally observed before in immunoprecipitates (7, 44). 
When present in immunoprecipitates,  the higher molecular 
mass class I is sometimes assumed to represent class I heavy 
chain with/32m still  associated.  However, we consider this 
possibility for the isolated Ly-m11 + K b subset very unlikely 
since  there was no change in the migration  of this  subset 
in gels run in the presence of 8 M urea and 100 mM dithio- 
threitol  (data not shown).  Since the pattern of mobility of 
the Ly-m11 + K b subset is diffuse,  this more likely suggests 
that differences  in glycosylation may be contributing to the 
observed heterogeneity between the two isolated  K b subsets. 
Consistent with this possibility, we found that upon Endo 
F treatment to remove N-linked carbohydrate structures, both 
K b subsets migrated coincidently. Murine class I molecules 
have  two or three N-linked  glycans with  K b usually pos- 
sessing two N-linked complex-type glycosylations at Asn-86 
and Asn-176  of the  OL1  and o~2 domains,  respectively (45). 
Microheterogeneity of murine class I molecules has been ob- 
served previously and has been attributed  to differences  in 
the carbohydrate structures attached to the heavy chain (6-8). 
Often two major subsets that differ in size as well as charge 
can be observed by two-dimensional gels from immunoprecipi- 
tations of some H-2 class I molecules (6,  7).  In some cases 
the decreased mobility and higher negative charge of one subset 
can be attributed at least in part to greater sialylation (6-8). 
Despite the fact that class I carbohydrate microheterogeneity 
has been shown to exist, we demonstrate in this report that 
at least two subsets of cell surface expressed K b, differing in 
N-linked carbohydrate modification can be independently iso- 
lated and analyzed biochemically and functionally. The higher 
molecular mass of the Ly-mll + K b may possibly be due to 
differences  in  its degree of sialylation  relative  to  the M1/ 
42  high K b subset. However, the relative resistance  of the Ly- 
mll + K b to NANAse treatment  suggests either that sialy- 
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or that sialylation may be responsible, but most of the sialic 
acid linkages are of a type that is resistant to routine NANAse 
treatment (41). An alternative or additional possibility is that 
the hyperglycosylated Ly-mll + K b may be modified by poly- 
N-acetyllactosamine (PL) addition(s) similar to ABO blood 
group antigens that can be found on RBC and hematopoi- 
etic cells (46). Multiple and variable lactosaminyl unit addi- 
tions can result in a mixture of multiple sizes of a glycopro- 
tein (46), observed as broadening and smearing in SDS-PAGE, 
similar  to what  we observe for the Lyom11 + K b subset. 
It has been observed previously that the N-linked carbo- 
hydrate on murine class I molecules may affect their recogni- 
tion by some monoclonal antibodies (9, 47). It is presently 
unclear why the Ly-m11 + K b subset is more readily eluted 
from the Y3 column than  the M1/42hig h K b subset.  How- 
ever, it is conceivable that  the affinity of the Y3 mAb for 
the Ly-m11 + subset may be diminished due to the apparent 
greater size of the carbohydrate side chains on the Ly-mll ~ 
K b subset. It is possible for the same reason, that the larger 
carbohydrate found on  the Ly-mll + K b subset negatively 
affects M1/42 mAb recognition possibly due to steric hin- 
drance, masking of an epitope or it lacks a specific carbohy- 
drate structure that may be involved in M1/42 recognition 
of class I.  Recognition  of K b complexes by the $19.8 (Ly- 
m11) mAb may be enhanced by certain carbohydrate struc- 
tures found on one, but not the other K b (M1/42hig  h) subset. 
Further studies will be required to determine the influence 
of N-linked carbohydrate structure on M1/42 and $19.8 an- 
tibody recognition  of K b molecules. 
It has been reported previously that N-linked carbohydrates 
are not required for CTL recognition  (9,  10).  Removal of 
N-linked carbohydrate from K k by Endo F treatment  does 
not affect allo-specific CTL proliferation (10), and amino acid 
substitutions at all three Asn carbohydrate attachment  sites 
on L a by site-directed mutagenesis  also did not result in a 
significant change in allo-CTL lysis of cells transfected with 
the  mutated  L a gene  (9).  Despite  observations  indicating 
that  the N-linked carbohydrates on class I  seem not to be 
required for CTL recognition,  the effects of the extent and 
composition of the class I carbohydrate side chains on CD8 § 
CTL recognition is not understood.  Our data suggest for 
the first time that the type of N-linked carbohydrate on class 
I is likely to affect TCR recognition of class I alloantigen. 
How might the carbohydrate expressed on the Ly-mll + K b 
subset negatively affect TCR recognition?  Several explana- 
tions are possible including:  (a) because of their larger size, 
the carbohydrate structures on the Ly-m11 + K b subset may 
sterically  block  TCR  interaction(s);  (b)  the  Ly-mll +  K b 
subset expresses carbohydrate with a high net negative charge 
due to a high degree of NANAse resistant sialylation or pos- 
sibly sulfation, resulting in repulsion between the TCR and 
class I; (c) the carbohydrate on the two K b subsets may affect 
the  conformation  of the  heavy chain  differentially;  subtle 
changes in class  I conformation  are known to affect TCR 
recognition (36, 48); (d) some combination of the above pos- 
sibilities.  We have treated the Ly-mll + K b subset with Endo 
F or NANAse to remove N-linked glycosylation or its ter- 
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minal  sialic  acids  respectively, in  order  to convert the Ly- 
re11 + K b subset to a functional TCR ligand, however with 
current  methods the K b in both subsets is not  sufficiently 
stable during enzyme treatments to assay for CTL recogni- 
tion  (data not  shown). 
The Ly-m11  epitope has been detected on the surface of 
a variety of normal and transformed cell types (18, 22). Al- 
most all spleen and lymph node cells and a portion of bone 
marrow  and  thymus cells  express  this K b and/52m-depen- 
dent epitope. Tumor cells derived from various hematopoi- 
etic cell  types from  C57BL/6  and  related  strains  are  also 
positive for this antigen. Consistent with these previous ob- 
servations,  we were able to purify Ly-m11 + K b from a va- 
riety of H-2  b expressing tumor cell types of hematopoietic 
origin. We have also attempted to purify the two K b subsets 
from normal spleen and thymus cells, however the yields of 
K b were not sufficient  to be tested in assays done with both 
K b  subsets  isolated  from  tumor  cells  (data  not  shown). 
Therefore, a direct comparision of K b subsets from normal 
and transformed cells has not been possible and their poten- 
tial structural and functional relationships remain unresolved. 
The two cell surface forms of K b that differ in their abil- 
ities to trigger antigen specific CTL may reflect antigen pre- 
sentation by class I in vivo. For example, different cells may 
express varying densities of the two functionally distinct K b 
subsets, perhaps as suggested by the differing relative yields 
of the subsets from different cell lines (Fig.  1 and data not 
shown), and this might, in certain circumstances, influence 
their abilities to serve as antigen presenting cells.  From our 
results, peptides load both subsets equally well, yet only the 
complexes of peptide and M1/42hi~  h K b serve as both a TCR 
and CD8 ligand and induce a response. If expression of the 
Ly-m11 + K b subset is high on a cell,  it may compete with 
the M1/42hig h subset for binding  to a limiting  peptide an- 
tigen,  and thus maintain  the density of the relevant ligand 
for TCR recognition at a level below that  for effective re- 
sponse. Further studies are necessary to determine whether 
this can indeed occur. 
Tumor cells, especially those with a highly metastatic pheno- 
type, are known to express altered carbohydrate moieties on 
some of their glycoproteins (46, 49).  It is conceivable that 
alteration of the carbohydrate structures expressed on tumor 
cell class I molecules could diminish or prevent its recogni- 
tion by the TCR, thus providing a means of escaping CD8 + 
T cell surveillance.  One of the modifications resulting from 
cell transformation  is increased addition of PL to N-linked 
carbohydrate chains (49). Since it is possible that PL may be 
responsible  for  the  larger  carbohydrate  found  on  the  Ly- 
mll + K b subset,  it may also be responsible for the failure 
of the K b subset to serve as a TCR ligand. 
Although  the  carbohydrate  on  the  Ly-mll +  K b subset 
might interfere with TCR recognition, it may be necessary 
for interaction with other class I binding receptors, e.g., Ly- 
49A and/or related family members (50-52). Ly-49A has re- 
cently been demonstrated to be a class I MHC binding receptor 
normally expressed on a subset of NK cells, that when en- 
gaged may negatively regulate NK lytic activity (50-52). The 
Ly-49 family belongs to the greater C-type lectin family and a related rat molecule, NKR-P1 specifically expressed on NK 
cells, has recently been demonstrated to bind carbohydrates 
(53). It is therefore possible that a specific carbohydrate struc- 
ture  linked  to  K b,  perhaps  as  displayed  by  the  Ly-mll § 
subset,  may  be  required  for  recognition  by  Ly-49 family 
member(s). 
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